Lifecare ASA

Director's Dealing • Apr 26, 2024

Lifecare AS Mandatory notification of trade

Lifecare AS Mandatory notification of trade

Bergen, Norway 26 April 2024: Hannibal Invest AS, a company closely associated

with Hans Hekland, member of the Board of Directors of LifeCare AS (the

"Company"), has on 26 April 2024 sold 150,000 shares in the Company at an

average price of NOK 3.05 per share.

Following this transaction, Hannibal Invest AS holds 50,000 shares in the

Company. The transaction is conducted to fund subscription of shares in the

rights issue announced by the Company on 25 April 2024. Please see further

details about the transaction in the attached form. This information is

subject to the disclosure requirements pursuant to section 5-12 of the

Norwegian Securities Trading Act.

About us

Lifecare AS is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, Lifecare AS, joacim.holter@lifecare.no, +47 40 05 90 40

Asle Wingsternes, Head of Communications & Public Affairs,

asle.wingsternes@lifecare.no, +47 41 61 42 52

This information is information that Lifecare AS is obliged to make public

pursuant to the EU Market Abuse Regulation. The information was submitted for

publication, through the agency of the contact persons set out above, at

2024-04-26 16:21 CEST.